On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 21 Article 3
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 21, 22 May 2003

Citation style for this article: Six C, Bouraoui L, Lévy-Bruhl D. Rubella in pregnant women and newborns in France: 2001 data from the Rénarub network. Euro Surveill. 2003;7(21):pii=2233. Available online:

Rubella in pregnant women and newborns in France: 2001 data from the Rénarub network

Caroline Six (, Laurence Bouraoui, Daniel Levy-Bruhl, Institut de Veille Sanitaire, Saint-Maurice, France, and the Rénarub network. Translated from reference 1 by the Eurosurveillance editorial team.

The Rénarub network, set up in 1976, is the principle source of information on the epidemiology of rubella in France (1, 2). Its objective is to collate, at national level, cases of rubella occurring during pregnancy and congenital rubella, and more widely, to evaluate the impact of vaccination policy and prevention measures put in place in France with the aim of eliminating congenital rubella. The full version of this article is available on the website of the Institut de Veille Sanitaire, including the new case definition, more detailed results (, and a list of laboratories participating in the network (

Material and methods
The Rénarub network

The Rénarub network unites the clinical diagnostic laboratories carrying out anti-rubella IgM serology. Information is gathered at two levels:

  • From the microbiologists who receive a bi-yearly request to report rubella infections diagnosed in pregnant women or newborn infants
  • From treating doctors, gynaecologists, obstetricians, and paediatricians who provide by questionnaire demographic, laboratory, and clinical information on the infected woman, newborn, or fetus.
    Participation is voluntary. The information gathered does not include follow up of live births from infected mothers.

Inclusion criteria and case definition
Every pregnant woman for whom the first positive IgM serology is identified in 2001 and/or every newborn or fetus with a diagnosis of rubella infection. Cases are notified to the Institut de Veille Sanitaire (InVS), which coordinates this surveillance network.

In order to better take into account the difficulty of confirming the laboratory diagnosis of rubella infection in pregnancy, new case definitions, in particular IgG avidity, were used from 2001 (see full case definition on the InVS website, Confirmed and probable cases are included for analysis and possible cases are excluded. When it is unclear whether primary infection or re-infection has occurred, the case is defined as an 'infection'. Women born outside France but whose infection was acquired in France, and whose antenatal care was provided in France are included in the analysis.

Participation of laboratories and doctors
In 2001, the participation level of laboratories that were invited within mainland France was almost 100% (271/272). Compared with 2000, two new laboratories joined the network and one withdrew because it was no longer carrying out anti-rubella IgM serology. The participation level among doctors was also very high (99%).

Cases counted in 2001 and incidence
In 2001, 162 rubella infections were reported by the laboratories. Only 38 met the case definitions. Among these 38 cases, 27 were confirmed primary infections (2 of which occurred around the time of conception, with maternal infection becoming apparent with a history of contact with a rubella case or a rash), 1 confirmed infection, 6 probable primary infections and 4 probable infections. Among these 38 women, 6 gave birth to a child with congenital rubella syndrome (CRS), 2 had spontaneous abortion, and 8 underwent medical termination of pregnancy (table 1). In the case of one of the spontaneous abortions and one of the medical terminations, the fetuses had probable CRS. The other 124 cases were excluded from the analysis for the following reasons: the woman was not pregnant (57), rubella infection was excluded (5), possible infections (5), missing information (9), lost to follow up (8), past rubella infection (29), post vaccination immunity (8), infection prior to conception (1), and case from 2000 (1). Thus the annual incidence of rubella infection in 2001 was 3.6 (confirmed cases) or 4.9 per 100 000 live births (if we add the probable cases), and for CRS, 0.78/100 000 live births (Births in 2000 - provisional data, INSEE,

Table 1. Clinical status of newborns and fetuses by outcome of pregnancy [primary infections (n = 27 confirmed and 6 probable) and infections (n=1 confirmed and 4 probable)], mainland France, 2001, Rénarub network

Outcome of pregnancy
Presence of malformation
Absence of malformation
Probable infection
Confirmed infection
Absence of infection
Infection status unknown
Termination of pregnancy
Spontaneous abortion

Characteristics of infected pregnant women
The average age of the 38 women was 23.3 years (range=17 to 38 years), while the average age of maternity in the general population in France is 29.4 years (Source: INSEE 2000). The proportion of women under 20 was 21%, an infection rate of 42.1/100 000 live births (table 2). The country of birth is known for 29 women. For 21 cases, this was mainland France. Among the women for whom previous obstetric history is known (37/38), 10 (27%) had had at least one previous pregnancy. Among the 31 women whose vaccination status was known, none had been vaccinated.

Cases preventable by post partum vaccination
Ten women had been pregnant at least once before and up to three times. At least 6 of them had been living in France during a previous pregnancy. Of these 6 women, 1 woman's serology was known to have been previously negative, and 5 had no known previous negative serology. None of these 6 women had been vaccinated. Had they been vaccinated immediately follow of a previous pregnancy, 1 CRS and one miscarriage of a fetus with probable CRS could have been prevented.

Table 2. Distribution by age of pregnant women infected with rubella, mainland France, 2001, Rénarub Network (n = 38)

Age group Number of cases % Rate of infection/100 000 live births
15-19 years
20-24 years
25-29 years
30-34 years
35-39 years

Following a study carried out in 2002 by a group of clinical diagnostic laboratories carrying out anti-rubella IgM serology, Rénarub's size has more than doubled, from 133 to 272 laboratories, making our network almost exhaustive at the present date. The participation of clinicians contacted to document the cases notified by the laboratories has also greatly improved over the years (62% in 1996, 78% in 1997, 92% in 1998, 94% in 1999, and 99% in 2000 and 2001).

One of the consequences of the new case definition, introducing the category of cases of probable infection occurring during pregnancy, has been that infections previously considered as confirmed are now categorised as probable. Twenty six percent of cases which would have been categorised as confirmed under the previous definition were categorised as probable in 2001. Trend analysis was carried out in 2001 for confirmed and probable cases, corresponding to cases included in the old case definition.

Figure 1. Incidence rate of rubella infections in pregnant women and congenital rubella syndrome, mainland France, 1978-2001, Rénarub network.

The incidence of rubella infection during pregnancy measured through Rénarub (figure 1) could be an underestimation since asymptomatic or atypical rubella is common, and not always diagnosed in pregnant women.

The trends in the incidence of CRS (1.1/100 000 live births in 1997, 0.4 in 1998, 0.1 in 199, 1.0 in 2000 and 0.8 in 2001) should be interpreted in the context of increasing participation of doctors in the network. Of 161 cases reported by the laboratories in 1997, 67 women had acquired rubella during pregnancy, but could not be included in the analysis because of lack of information or lack of response from the treating doctor. In 2001, only 17 women who acquired rubella during pregnancy had to be excluded from analysis due to lack of information. Medical terminations of pregnancy, indicators of good surveillance during pregnancy but also of a lack of protective immunity in pregnant women, represent significant proportions of all women infected with rubella during pregnancy (26% in 1997, 12% in 1998, 33% in 1999, 30% in 2000, and 21% in 2001). They can include congenital rubella infections leading to fetal damage not counted in the calculations of CRS incidence. Finally, if seroconversion during pregnancy is not identified, it is likely that cases of CRS will not be identified at birth.

In 2001, 86% of infected women were under 30 years, which demonstrates that this virus continues to circulate among young adults. This is a consequence of poor vaccination coverage in children (84% at 2 years in 2000, and 90% at 6 years in 1999), resulting in insufficient herd immunity to interrupt transmission (4). A seroepidemiological study carried out in 1998, based on sera taken from the general population in seven western European countries, places France, along with Italy, as a country with high susceptibility (>10%). The reservoir of susceptible people in France is particularly significant among teenage boys (14% of 10-14 year olds, and 21% of 15-19 year olds) and girls (17% and 12% respectively) (5). This latter group who are near to reproductive age, are particularly at risk. They have not benefited from high vaccination coverage in childhood, may have missed boosters at 6 years or at adolescence, and have grown up in an environment with a low rubella incidence making it unlikely that they have been protected by natural rubella infection acquired in childhood.

Even if the absolute number of CRS identified each year by the Rénarub surveillance network is low, the fact that these cases continue to occur in France today, including in multiparous women, is difficult to accept. The vaccine is easily accessible, very effective, and safe. It has been recommended for almost 30 years for adolescents, and actively promoted for infants for almost 20 years, and routine screening for anti-rubella immunity is an obligatory part of pre-conceptual and antenatal care.

In addition to the need to rapidly increase infant vaccination coverage throughout the country, the priority is to reinforce catch-up immunisation of non immune girls and women of reproductive age. Failing that, serological studies predict that new outbreaks of rubella infection during pregnancy will occur, leading to terminations of pregnancy and above all congenital abnormalities in infants. It is also important for clinicians to carry out post partum vaccination for women identified as seronegative during pregnancy in a more systematic way.


  1. Six C, Bouraoui L, Levy-Bruhl D, and the scientists of the Rénarub network. La rubéole chez la femme enceinte et le nouveau-né en France métropolitaine en 2000: les données 2001 du réseau Rénarub. Bulletin Epidémiologique Hebdomadaire 2003; (21):93-4. ( [in French]
  2. Six C, Bouraoui L, Levy-Bruhl D and the scientists of the Rénarub network - La rubéole chez la femme enceinte et le nouveau-né en France métropolitaine en 2000. Surveillance nationale des maladies infectieuses 1998-2000. Editions InVS, Saint-Maurice, 2003.
  3. Grangeot-Keros L, Audibert F. Infections virales et toxoplasmose maternofœtales. Paris: Editions scientifiques et médicales Elsevier SAS; 2001. p. 59-71.
  4. Bussiere E. Principaux indicateurs issus des certificats de santé. Drees, Working document, No. 17. December 2000. ( [in French, accessed 22 May 2003]
  5. Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, Olin P, Berbers G, Rebiere I, et al. The seroepidemiology of rubella in western Europe. Epidemiol Infect 2000; 125: 347-57.

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.